Our analysis concludes Menlo Therapeutics' (MNLO) enterprise valuation of $215 million at $2.00/share is materially undervalued, considering like companies in MNLO's industry (dermatology) have been acquired for at least 2 times estimated peak annual sales, because:
- estimated peak annual sales from MNLO's FDA approved product called AMZEEQ, launched in January 2020, should be greater than, or at least equal to, $200 million/year AND:
- the PDUFA date of 6/2/2020 is rapidly approaching for a second MNLO product estimated to generate peak annual sales, assuming approved by the FDA, of also greater than, or at least equal